Study (Year)
|
Subjects (n, % Female, Mean Age)
|
Treatment Arms
|
Mean Follow-Up Period
|
Primary End Point as Reported
|
RRR* (95% CI), P
|
Event Rate (%)
|
| CLARITY TIMI28 (2005)68 |
Acute STEMI (<12 hours); Rx Lysis, ASA, ±heparin (3491, 19.7, 57 years) |
Clopidogrel 300 mg bolus, 75 mg once daily vs placebo |
3.5 d |
Occluded infarct-related artery, death, MI prior to angiography (odds reduction of end point, 36%; 95% CI, 24 to 47; P<0.001) |
30.9 |
15 |
|
|
|
21.7 |
| PCI-CLARITY TIMI 28 (2005)69 |
Acute STEMI (<12 hours); Rx Lysis, ASA, ±heparin, & subsequent PCI (1863, 18.3, 57.3 years) |
Clopidogrel 300 mg bolus, 75 mg once daily vs placebo and clopidogrel after angiogram |
30 d |
Cardiovascular death, MI, CVA from PCI to 30 days after randomization (adjusted OR, 0.54; 95% CI, 0.35 to 0.85; P=0.008) |
41.9 |
3.6 |
|
|
|
6.2 |
| COMMIT (CCS-2) (2005)70 |
Suspected acute MI; Rx Lysis 54%, heparin (45 852, 28, 61 years) |
Clopidogrel (no bolus) 75 mg once daily+ASA 162 mg once daily vs placebo+ASA 162 mg once daily |
Discharge date or 28 d |
Death, reinfarction, CVA (all-cause mortality RRR, 7% [1 to 13]; P=0.03) |
9.0 (3.0 to 14.0), P=0.002 |
9.2 |
|
10.1 |
| CURE (2001)71 |
Acute coronary syndrome (12 562, 38.5%, 64.2 years) |
Clopidogrel 300 mg bolus, 75 mg once daily+ASA 75 to 325 mg vs placebo+ASA 75 to 325 mg |
9 m |
Cardiovascular death, nonfatal MI, CVA (RR, 0.80; 95% CI, 0.72 to 0.90; P<0.001) |
20.0 |
9.3 |
|
|
|
11.4 |
| PCI-CURE (2001)72 |
Acute coronary syndrome on PCI (2658, 30.2%, 61.5 years) |
Clopidogrel 300 mg bolus, 75 mg once daily+ASA 75 to 325 mg vs placebo+ASA 75 to 325 mg |
8 m |
Cardiovascular death, MI, urgent target vessel revascularization (<30 days) (RR, 0.70; 95% CI, 0.50 to 0.97; P=0.03) |
30.0 |
4.5 |
|
|
|
6.4 |
| CREDO (2002)73 |
Elective PCI or high likelihood of PCI (2116, 28.7%, 61.7 years) |
Clopidogrel 300 mg bolus, 75 mg once daily+ASA 325 mg vs placebo+ASA 325 mg |
1 y |
Death, MI, CVA |
26.9 (3.9 to 44.4), P=0.02 |
8.5 |
|
|
11.5 |
| CAPRIE (1996)67 |
Recent MI, CVA, or PAD (19 185, 28%, 62.5 years) |
Clopidogrel 75 mg once daily vs ASA 325 mg |
1.9 y |
Ischemic stroke, MI, vascular death |
8.7 (0.3 to 16.5), P=0.043 |
5.32 |
|
|
5.83 |
| CHARISMA (2006)74 |
Clinically evident CAD or multiple risk factors (15 603, 29.8%, 64 years) |
Clopidogrel 75 mg+ASA 75 to 162 mg vs placebo+ASA 75 to 162 mg |
28 m |
Cardiovascular death, MI, CVA (RR, 0.93; 95% CI, 0.83 to 1.05; P=0.22) |
7.0 |
6.8 |
|
|
|
7.3 |
| MATCH (2004)75 |
Recent ischemic CVA or TIA (7599, 37%, 66.3 years) |
Clopidogrel 75 mg+ASA 75 mg once daily vs clopidogrel 75 mg+placebo |
18 m |
Ischemic CVA, MI, vascular death, or rehospitalization for acute ischemia |
6.4 (4.6 to 16.3), P=0.24 |
15.7 |
|
|
16.7 |
| ACTIVE-W (2005)76 |
A fib and  1 stroke risk factor (6706, 23.5%, 70.2 years)
|
Clopidogrel 75 mg once daily and ASA 75 to 100 mg vs warfarin
|
1.28 y |
Stroke, non–central nervous system systemic embolism, MI, and vascular mortality (RR, 1.44; 95% CI, 1.18 to 1.76; P=0.0003)
|
43.5 (increased risk)
|
5.64 |
|
|
3.93 |
|
| OR indicates odds ration; RR, relative risk; RRR, relative risk reduction; and TIA, transient ischemic attack. |
| *Crude calculation from reported primary point event rate when not available in published results (95% CI provided when available). |
| Median value. |
